Evaluation of PCV Schedules in a Naive Population in Vietnam
Launched by NAGASAKI UNIVERSITY · Nov 8, 2016
Trial Information
Current as of May 24, 2025
Completed
Keywords
ClinConnect Summary
Background Pneumococcal conjugate vaccine (PCVs) have substantially reduced the burden of pneumococcal disease. WHO currently recommends giving PCVs as 3 doses - either 3 doses in infancy with Pentavalent vaccine (3p+0), or two doses in infancy followed by a booster around the end of the first year of life (2p+1). The 3p+0 schedule is used in many countries introducing PCV with Gavi support while several European countries are using 2p+1 schedule. However, their high price and the current recommendation for at least 3 doses to achieve full individual protection for infants, introduces a sub...
Gender
ALL
Eligibility criteria
- • Inclusion Criteria: All children living in the intervention communes in Nha Trang city, whose parents or guardian give informed consent will be eligible to receive PCV in accordance with their age.
- • Exclusion Criteria: Children who are not fit enough to receive national vaccination program vaccine for health reason (eg.fever, currently under medication due to illness such as pneumonia, diarrhea, etc) in accordance with Vietnam national immunization guidelines. This will be decided by the medical doctor in charge of the vaccination at commune health center in accordance with Vietnamese guideline.
About Nagasaki University
Nagasaki University is a prestigious institution located in Nagasaki, Japan, recognized for its commitment to advancing medical research and education. As a clinical trial sponsor, the university leverages its robust academic resources and expertise in various fields of health sciences to conduct innovative clinical studies aimed at improving patient outcomes and understanding disease mechanisms. With a focus on ethical standards and regulatory compliance, Nagasaki University collaborates with multidisciplinary teams to facilitate groundbreaking research that addresses critical health challenges both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nha Trang, Khanh Hoa, Vietnam
Patients applied
Trial Officials
LAYMYINT YOSHIDA, MBBS, PhD
Principal Investigator
Institute of Tropical Medicine, Nagasaki University, Nagasaki
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials